腎細胞がんの世界市場レポート 2025年

腎細胞がん市場規模は、今後数年間で力強い成長が見込まれます。2029年にはCAGR6.6％で9億5,000万米ドルに成長します。今後は、個別化医療の普及、がんの早期発見に対する意識の高まり、がん医療へのヘルスケア投資の増加、医療へのアクセスの向上、新規治療に焦点を当てた臨床試験や調査の急増などが予測期間の成長を牽引するとみられます。予測期間の主な動向としては、精密診断のための人工知能の統合、標的療法の開発、免疫療法の革新、バイオマーカー同定の進歩、低侵襲手術技術の採用、画像技術の改善などが挙げられます。

高齢者人口の増加が腎細胞がん市場の拡大を牽引すると予想されます。一般的に65歳以上と定義される高齢者は、ヘルスケアや社会的ニーズが独特であることが多いです。この人口層の成長は、ヘルスケアの進歩、栄養状態の改善、寿命の延長に起因しています。腎細胞がん（RCC）は高齢者の間で一般的になりつつあり、このグループのための専門的なスクリーニングと治療アプローチの必要性を強調しています。例えば、2024年1月、米国の非営利団体である人口問題研究所の報告書によると、65歳以上の米国人の数は2022年の5,800万人から2050年には8,200万人となり、47％増加すると予測されています。その結果、高齢化が腎細胞がん市場の成長に寄与しています。

腎細胞がん市場の企業は、技術の進歩、特にがんの診断と治療を強化するための人工知能（AI）の活用に注力しています。腎生検を分析するために設計されたものなど、AIを搭載したソリューションは、診断精度の向上、手順の合理化、患者の転帰の最適化を目的として開発されています。これらのAIツールは、機械学習アルゴリズムとコンピュータ・ビジョンを用いて、病理医や腎臓専門医による腎臓組織サンプルの評価を支援します。例えば、2024年3月、オランダに本社を置くソフトウェア会社アイオシンは、腎生検解析のためのAI搭載ソリューションであるNephroPathプラットフォームを発表しました。NephroPathは、腎生検の組織学的バイオマーカーの解析に計算病理学的アルゴリズムを採用し、組織タイプの特定、間質性線維症の測定、糸球体の評価などを行う。このAI駆動型テクノロジーは、腎病理バイオマーカーの一貫性、詳細性、再現性のあるスコアリングを保証し、従来のスコアリング手法の限界に対処し、観察者のバイアスを低減します。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- マクロ経済シナリオ金利、インフレ、地政学、新型コロナウイルス感染症の影響と回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界腎細胞がんPESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界の腎細胞がん市場：成長率分析
• 世界の腎細胞がん市場の実績：規模と成長, 2019-2024
• 世界の腎細胞がん市場の予測：規模と成長, 2024-2029, 2034F
• 世界腎細胞がん総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の腎細胞がん市場：タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• クリアセル腎細胞がん（RCC）
• 乳頭状腎細胞がん（腎細胞がん）
• クロモフォブ腎細胞がん（RCC）
• 世界の腎細胞がん市場診断別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 尿検査
• コンピュータ断層撮影（CT）スキャン
• 腎摘出術
• 血液検査
• 超音波
• 生検
• 世界の腎細胞がん市場治療別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 薬
• アブレーション
• 標的療法
• 化学療法
• 手術
• その他の治療法
• 世界の腎細胞がん市場：エンドユーザー別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院
• 専門クリニック
• ホームケア
• その他のエンドユーザー
• 世界の腎細胞がん市場、明細胞腎細胞がん（RCC）のサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 散発性明細胞腎細胞がん
• 遺伝性明細胞腎細胞がん
• 世界の腎細胞がん市場乳頭がんのサブセグメンテーション腎細胞がん（RCC）、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 1型乳頭状腎細胞がん
• 2型乳頭状腎細胞がん
• 世界の腎細胞がん市場、好色性細菌腎細胞がん（RCC）のサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 古典的な嫌色性腎細胞がん
• ハイブリッドクロモフォブRCC

第7章 地域別・国別分析

• 世界の腎細胞がん市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界の腎細胞がん市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 腎細胞がん市場：競合情勢
• 腎細胞がん市場：企業プロファイル
  • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Johnson & Johnson Overview, Products and Services, Strategy and Financial Analysis
  • F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Bayer AG Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Bristol Myers Squibb Company
• AstraZeneca Plc
• Abbott Laboratories
• Novartis AG
• Fresenius Kabi AG
• GSK plc
• Takeda Pharmaceutical Company Limited
• Amgen Inc.
• Viatris Inc.（Mylan N.V.）
• Astellas Pharma Inc.
• Eisai Co. Ltd.
• Sun Pharmaceutical Industries Ltd.
• Ipsen Pharma
• Cipla Inc.
• Hikma Pharmaceuticals PLC

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 腎細胞がん市場2029：新たな機会を提供する国
• 腎細胞がん市場2029：新たな機会を提供するセグメント
• 腎細胞がん市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Renal cell carcinoma (RCC) is a type of kidney cancer that originates in the renal tubules, which are responsible for filtering waste and producing urine. The cancer develops when kidney cells become abnormal and begin growing uncontrollably, forming a tumor that can impair the kidney's ability to filter waste and produce urine.

The primary types of renal cell carcinoma include clear cell RCC, papillary RCC, and chromophobe RCC. Clear cell RCC is the most common form of kidney cancer, arising in the kidney's blood-filtering tubules. Microscopically, the cancer cells appear clear or pale due to the accumulation of lipids and carbohydrates. Diagnosis typically involves a combination of urine and blood tests, computed tomography (CT) scans, ultrasounds, nephrectomy, and biopsies. Treatment options include surgery, targeted therapies, chemotherapy, ablation, medications, and other methods, serving a variety of settings such as hospitals, specialty clinics, home care, and other healthcare providers.

The renal cell carcinoma market research report is one of a series of new reports from The Business Research Company that provides renal cell carcinoma market statistics, including the renal cell carcinoma industry's global market size, regional shares, competitors with a renal cell carcinoma market share, detailed renal cell carcinoma market segments, market trends and opportunities, and any further data you may need to thrive in the renal cell carcinoma industry. This renal cell carcinoma market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The renal cell carcinoma market size has grown strongly in recent years. It will grow from $0.69 billion in 2024 to $0.74 billion in 2025 at a compound annual growth rate (CAGR) of 7.0%. The growth observed in the historical period can be attributed to several factors, including the increasing prevalence of kidney cancer, a growing geriatric population, wider adoption of targeted therapies, enhanced awareness of cancer screening, improvements in healthcare infrastructure, and a rise in investments in oncology research and development.

The renal cell carcinoma market size is expected to see strong growth in the next few years. It will grow to $0.95 billion in 2029 at a compound annual growth rate (CAGR) of 6.6%. Looking forward, the growth in the forecast period is expected to be driven by the growing adoption of personalized medicine, increasing awareness about early cancer detection, rising healthcare investments in oncology, better access to healthcare, and a surge in clinical trials and research focused on novel therapies. Key trends for the forecast period include the integration of artificial intelligence for precision diagnostics, the development of targeted therapies, innovations in immunotherapy, advancements in biomarker identification, the adoption of minimally invasive surgical techniques, and improvements in imaging technologies.

The increasing geriatric population is anticipated to drive the expansion of the renal cell carcinoma market. The elderly, typically defined as individuals aged 65 and above, often have unique healthcare and social needs. The growth in this demographic is attributed to advancements in healthcare, improved nutrition, and longer life expectancy. Renal cell carcinoma (RCC) is becoming more common among older adults, underscoring the need for specialized screening and treatment approaches for this group. For example, in January 2024, a report by the Population Reference Bureau, a US-based non-profit organization, predicted that the number of Americans aged 65 and older will rise from 58 million in 2022 to 82 million by 2050, marking a 47% increase. Consequently, the aging population is contributing to the growth of the renal cell carcinoma market.

Companies in the renal cell carcinoma market are focusing on technological advancements, particularly in the use of artificial intelligence (AI) to enhance cancer diagnosis and treatment. AI-powered solutions, such as those designed to analyze kidney biopsies, are being developed to improve diagnostic accuracy, streamline procedures, and optimize patient outcomes. These AI tools use machine learning algorithms and computer vision to assist pathologists and nephrologists in evaluating kidney tissue samples. For example, in March 2024, Aiosyn, a software company based in the Netherlands, introduced the NephroPath platform, an AI-powered solution for kidney biopsy analysis. NephroPath employs computational pathology algorithms to analyze histological biomarkers in kidney biopsies, including identifying tissue types, measuring interstitial fibrosis, and assessing glomeruli. This AI-driven technology ensures consistent, detailed, and reproducible scoring of renal pathology biomarkers, addressing limitations of traditional scoring methods and reducing observer bias.

In October 2024, Arcus Biosciences, a US-based biotechnology firm, partnered with AstraZeneca plc to investigate the combination of casdatifan (AB521) and volrustomig for patients with clear cell renal cell carcinoma (ccRCC). The partnership aims to advance treatment for ccRCC by developing a new drug combination, combining the expertise of both companies to accelerate development and improve patient outcomes. AstraZeneca plc, a UK-based pharmaceutical company, is known for its focus on oncology treatments and diagnoses.

Major players in the renal cell carcinoma market are Pfizer Inc., Johnson & Johnson, F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Bayer AG, Bristol Myers Squibb Company, AstraZeneca Plc, Abbott Laboratories, Novartis AG, Fresenius Kabi AG, GSK plc, Takeda Pharmaceutical Company Limited, Amgen Inc., Viatris Inc. (Mylan N.V.), Astellas Pharma Inc., Eisai Co. Ltd., Sun Pharmaceutical Industries Ltd., Ipsen Pharma, Cipla Inc., Hikma Pharmaceuticals PLC, Amneal Pharmaceuticals LLC, Exelixis Inc., Nektar Therapeutics.

North America was the largest region in the renal cell carcinoma market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in renal cell carcinoma report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the renal cell carcinoma market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The renal cell carcinoma market consists of revenues earned by entities by providing services such as CT scans, ultrasounds, chemotherapy and targeted therapy, immunotherapy, and supportive care and counseling. The market value includes the value of related goods sold by the service provider or included within the service offering. The renal cell carcinoma market also includes sales of needle biopsy systems, laser ablation devices, biopsy trays and kits, and biopsy specimen containers. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Renal Cell Carcinoma Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on renal cell carcinoma market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for renal cell carcinoma ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The renal cell carcinoma market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Type: Clear Cell Renal Cell Carcinoma (RCC); Papillary Renal Cell Carcinoma (RCC); Chromophobe Renal Cell Carcinoma (RCC)
• 2) By Diagnosis: Urine Tests; Computed Tomography (CT) Scan; Nephrectomy; Blood Tests; Ultrasound; Biopsy
• 3) By Treatment: Medication; Ablation; Targeted Therapy; Chemotherapy; Surgery; Other Treatments
• 4) By End-Users: Hospitals; Specialty Clinics; Homecare; Other End-Users
• Subsegments:
• 1) By Clear Cell Renal Cell Carcinoma (RCC): Sporadic Clear Cell RCC; Hereditary Clear Cell RCC
• 2) By Papillary Renal Cell Carcinoma (RCC): Type 1 Papillary RCC; Type 2 Papillary RCC
• 3) By Chromophobe Renal Cell Carcinoma (RCC): Classic Chromophobe RCC; Hybrid Chromophobe RCC
• Companies Mentioned: Pfizer Inc.; Johnson & Johnson; F. Hoffmann-La Roche Ltd.; Merck & Co. Inc.; Bayer AG
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Renal Cell Carcinoma Market Characteristics

3. Renal Cell Carcinoma Market Trends And Strategies

4. Renal Cell Carcinoma Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Renal Cell Carcinoma Growth Analysis And Strategic Analysis Framework

• 5.1. Global Renal Cell Carcinoma PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Renal Cell Carcinoma Market Growth Rate Analysis
• 5.4. Global Renal Cell Carcinoma Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Renal Cell Carcinoma Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Renal Cell Carcinoma Total Addressable Market (TAM)

6. Renal Cell Carcinoma Market Segmentation

• 6.1. Global Renal Cell Carcinoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Clear Cell Renal Cell Carcinoma (RCC)
• Papillary Renal Cell Carcinoma (RCC)
• Chromophobe Renal Cell Carcinoma (RCC)
• 6.2. Global Renal Cell Carcinoma Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Urine Tests
• Computed Tomography (CT) Scan
• Nephrectomy
• Blood Tests
• Ultrasound
• Biopsy
• 6.3. Global Renal Cell Carcinoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Medication
• Ablation
• Targeted Therapy
• Chemotherapy
• Surgery
• Other Treatments
• 6.4. Global Renal Cell Carcinoma Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Specialty Clinics
• Homecare
• Other End-Users
• 6.5. Global Renal Cell Carcinoma Market, Sub-Segmentation Of Clear Cell Renal Cell Carcinoma (RCC), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Sporadic Clear Cell RCC
• Hereditary Clear Cell RCC
• 6.6. Global Renal Cell Carcinoma Market, Sub-Segmentation Of Papillary Renal Cell Carcinoma (RCC), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Type 1 Papillary RCC
• Type 2 Papillary RCC
• 6.7. Global Renal Cell Carcinoma Market, Sub-Segmentation Of Chromophobe Renal Cell Carcinoma (RCC), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Classic Chromophobe RCC
• Hybrid Chromophobe RCC

7. Renal Cell Carcinoma Market Regional And Country Analysis

• 7.1. Global Renal Cell Carcinoma Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Renal Cell Carcinoma Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Renal Cell Carcinoma Market

• 8.1. Asia-Pacific Renal Cell Carcinoma Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Renal Cell Carcinoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Renal Cell Carcinoma Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Renal Cell Carcinoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Renal Cell Carcinoma Market

• 9.1. China Renal Cell Carcinoma Market Overview
• 9.2. China Renal Cell Carcinoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Renal Cell Carcinoma Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Renal Cell Carcinoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Renal Cell Carcinoma Market

• 10.1. India Renal Cell Carcinoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Renal Cell Carcinoma Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Renal Cell Carcinoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Renal Cell Carcinoma Market

• 11.1. Japan Renal Cell Carcinoma Market Overview
• 11.2. Japan Renal Cell Carcinoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Renal Cell Carcinoma Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Renal Cell Carcinoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Renal Cell Carcinoma Market

• 12.1. Australia Renal Cell Carcinoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Renal Cell Carcinoma Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Renal Cell Carcinoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Renal Cell Carcinoma Market

• 13.1. Indonesia Renal Cell Carcinoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Renal Cell Carcinoma Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Renal Cell Carcinoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Renal Cell Carcinoma Market

• 14.1. South Korea Renal Cell Carcinoma Market Overview
• 14.2. South Korea Renal Cell Carcinoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Renal Cell Carcinoma Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Renal Cell Carcinoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Renal Cell Carcinoma Market

• 15.1. Western Europe Renal Cell Carcinoma Market Overview
• 15.2. Western Europe Renal Cell Carcinoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Renal Cell Carcinoma Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Renal Cell Carcinoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Renal Cell Carcinoma Market

• 16.1. UK Renal Cell Carcinoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Renal Cell Carcinoma Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Renal Cell Carcinoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Renal Cell Carcinoma Market

• 17.1. Germany Renal Cell Carcinoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Renal Cell Carcinoma Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Renal Cell Carcinoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Renal Cell Carcinoma Market

• 18.1. France Renal Cell Carcinoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Renal Cell Carcinoma Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Renal Cell Carcinoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Renal Cell Carcinoma Market

• 19.1. Italy Renal Cell Carcinoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Renal Cell Carcinoma Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Renal Cell Carcinoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Renal Cell Carcinoma Market

• 20.1. Spain Renal Cell Carcinoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Renal Cell Carcinoma Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Renal Cell Carcinoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Renal Cell Carcinoma Market

• 21.1. Eastern Europe Renal Cell Carcinoma Market Overview
• 21.2. Eastern Europe Renal Cell Carcinoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Renal Cell Carcinoma Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Renal Cell Carcinoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Renal Cell Carcinoma Market

• 22.1. Russia Renal Cell Carcinoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Renal Cell Carcinoma Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Renal Cell Carcinoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Renal Cell Carcinoma Market

• 23.1. North America Renal Cell Carcinoma Market Overview
• 23.2. North America Renal Cell Carcinoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Renal Cell Carcinoma Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Renal Cell Carcinoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Renal Cell Carcinoma Market

• 24.1. USA Renal Cell Carcinoma Market Overview
• 24.2. USA Renal Cell Carcinoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Renal Cell Carcinoma Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Renal Cell Carcinoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Renal Cell Carcinoma Market

• 25.1. Canada Renal Cell Carcinoma Market Overview
• 25.2. Canada Renal Cell Carcinoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Renal Cell Carcinoma Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Renal Cell Carcinoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Renal Cell Carcinoma Market

• 26.1. South America Renal Cell Carcinoma Market Overview
• 26.2. South America Renal Cell Carcinoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Renal Cell Carcinoma Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Renal Cell Carcinoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Renal Cell Carcinoma Market

• 27.1. Brazil Renal Cell Carcinoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Renal Cell Carcinoma Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Renal Cell Carcinoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Renal Cell Carcinoma Market

• 28.1. Middle East Renal Cell Carcinoma Market Overview
• 28.2. Middle East Renal Cell Carcinoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Renal Cell Carcinoma Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Renal Cell Carcinoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Renal Cell Carcinoma Market

• 29.1. Africa Renal Cell Carcinoma Market Overview
• 29.2. Africa Renal Cell Carcinoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Renal Cell Carcinoma Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Renal Cell Carcinoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Renal Cell Carcinoma Market Competitive Landscape And Company Profiles

• 30.1. Renal Cell Carcinoma Market Competitive Landscape
• 30.2. Renal Cell Carcinoma Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Johnson & Johnson Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Bayer AG Overview, Products and Services, Strategy and Financial Analysis

31. Renal Cell Carcinoma Market Other Major And Innovative Companies

• 31.1. Bristol Myers Squibb Company
• 31.2. AstraZeneca Plc
• 31.3. Abbott Laboratories
• 31.4. Novartis AG
• 31.5. Fresenius Kabi AG
• 31.6. GSK plc
• 31.7. Takeda Pharmaceutical Company Limited
• 31.8. Amgen Inc.
• 31.9. Viatris Inc. (Mylan N.V.)
• 31.10. Astellas Pharma Inc.
• 31.11. Eisai Co. Ltd.
• 31.12. Sun Pharmaceutical Industries Ltd.
• 31.13. Ipsen Pharma
• 31.14. Cipla Inc.
• 31.15. Hikma Pharmaceuticals PLC

32. Global Renal Cell Carcinoma Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Renal Cell Carcinoma Market

34. Recent Developments In The Renal Cell Carcinoma Market

35. Renal Cell Carcinoma Market High Potential Countries, Segments and Strategies

• 35.1 Renal Cell Carcinoma Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Renal Cell Carcinoma Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Renal Cell Carcinoma Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer